Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy | MicrobiomeTrials← Back to trialsNCT06502990
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
TERMINATEDPHASE3INTERVENTIONAL
Trial Details
Start: 2025-05-23Est. Completion: 2026-02-11
Enrollment target: 1 participants Locations- UZ Leuven, Leuven, Leuven, Belgium
- Hôpital Necker - Enfants Malades, Paris, Paris, France
- Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Universitaire Robert-Debre, Paris, France
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Free and Hanseatic City of Hamburg, Germany
- Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin, Ulm, Ulm, Germany
- IRCCS Ospedale Pediatrico Bambino Gesù, Chieti, Chieti, Italy
- Azienda Ospedaliera Universitaria "Federico II", Naples, Naples, Italy
- Azienda Ospedaliero Universitaria Maggiore della Carità di Novara, Novara, Novara, Italy
- Azienda Ospedaliero-Universitaria di Parma, Parma, Parma, Italy
- Azienda Ospedaliero Universitaria Pisana, Pisa, Pisa, Italy
- IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Rome, Italy
- Ospedale Filippo Del Ponte Varese - ASST Sette Laghi, Varese, Varese, Italy
Other microbiome trials you might be interested in
Generalized Lipodystrophy
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who hav…
Bethesda, United StatesCompleted Jul 9, 2026
LipodystrophyDiabetesHyperlipidemia
Background:
\- Generalized lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to he…
Bethesda, United StatesEst. completion Jul 31, 2027